A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris

PHASE2CompletedINTERVENTIONAL
Enrollment

366

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

September 30, 2009

Conditions
Acne Vulgaris
Interventions
DRUG

Low Strength IDP-107

Once a day for 12 weeks

DRUG

High Strength IDP-107

Once a day for 12 weeks

DRUG

Placebo Comparator

Once a day for 12 weeks

Trial Locations (25)

11790

DermResearchCenter of New York, Inc., Stony Brook

14623

Dermatology Associates of Rochester, Rochester

23507

Virginia Clinical Research, Inc., Norfolk

27599

University of North Carolina Hospitals and School of Medicine, Chapel Hill

33175

FXM Research Corp., Miami

48038

Michigan Center for Skin Care Research, Clinton Township

48059

Hamzavi Dermatology, Fort Gratiot

53719

Madison Skin & Research, Inc., Madison

55432

Minnesota Clinical Study Center, Fridley

68144

Skin Specialist, PC, Omaha

71913

Burke Pharmaceutical Research, Hot Springs

72205

Dermatology Research of Arkansas, PLLC, Little Rock

73104

University of Oklahoma Health Sciences Center, Oklahoma City

76011

Arlington Research Center, Inc., Arlington

77056

The Center for Skin Research, Houston

77802

J & S Studies, Inc., Bryan

78759

DermResearch, Inc., Austin

80209

Cherry Creek Research, Inc., Denver

84088

South Valley Dermatology, West Jordan

87106

Academic Dermatology Associates, Albuquerque

90404

Clinical Science Institute, Santa Monica

92123

RADY Children's Hospital - San Diego, San Diego

94589

Solano Clinical Research, Vallejo

97210

Oregon Dermatology and Research Center, Portland

99204

Premier Clinical Research, Spokane

Sponsors
All Listed Sponsors
lead

Dow Pharmaceutical Sciences

INDUSTRY